Who Should Not Take Semaglutide Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2)
Compounded Semaglutide is more affordable than brand-name options, which can cost $1,000+ per month without insurance
Chronobiologia 4 , 217246 (1977)
Phase 2 obesity trial (NEJM 2023) adverse events by maintenance dose (where a dose had two escalation arms, the range across both arms is shown): Phase 2 type 2 diabetes trial (Lancet 2023): mild-to-moderate gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were reported in 35% of retatrutide participants ranging from 13% at 0.5 mg to 50% in the 8 mg fast-escalation group compared with 13% on placebo and 35% on dulaglutide 1.5 mg
GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response
5 g per well of cell membrane was incubated with furimazine (1:1,000 dilution from stock) in assay buffer (1 HBSS, 10 mM HEPES, 0.1% (w/v) BSA, 1 P8340 protease inhibitor cocktail, 1 mM DTT and 0.1 mM PMSF, pH 7.4)